DexCom SG&A increased by 8.8% to $349.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.8%, from $310.10M to $349.70M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 12.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $186.50M | $198.50M | $237.40M | $218.90M | $248.90M | $234.60M | $305.30M | $296.40M | $299.00M | $286.40M | $303.60M | $319.30M | $332.70M | $306.40M | $327.40M | $310.10M | $328.00M | $331.40M | $321.50M | $349.70M |
| QoQ Change | — | +6.4% | +19.6% | -7.8% | +13.7% | -5.7% | +30.1% | -2.9% | +0.9% | -4.2% | +6.0% | +5.2% | +4.2% | -7.9% | +6.9% | -5.3% | +5.8% | +1.0% | -3.0% | +8.8% |
| YoY Change | — | — | — | — | +33.5% | +18.2% | +28.6% | +35.4% | +20.1% | +22.1% | -0.6% | +7.7% | +11.3% | +7.0% | +7.8% | -2.9% | -1.4% | +8.2% | -1.8% | +12.8% |